nab-Paclitaxel for the treatment of pancreatic cancer

References

• American Cancer SocietyCancer Facts and Figures 2016Atlanta, GAAmerican Cancer Society2016
   Google Scholar
• Surveillance, Epidemiology, and End Results ProgramSEER stat facts sheets: pancreas cancer updated 2016. Available from: http://seer.cancer.gov/statfacts/html/pancreas.htmlAccessed September 15, 2016
   Google Scholar
• CilibertoDBottaCCorrealePRole of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trialsEur J Cancer201349359360322989511
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• GoldsteinDEl-MaraghiRHHammelPnab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialJ Natl Cancer Inst20151072110
   Google Scholar
• NCCN Clinical Practice Guidelines in OncologyPancreatic AdenocarcinomaV12016 Available form: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAccessed August 1, 2016
   Google Scholar
• DucreuxMCuhnaASCaramellaCCancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v56v6826314780
   PubMed Web of Science ®Google Scholar
• BalabanEPManguPBKhoranaAALocally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201634222654266827247216
   PubMed Web of Science ®Google Scholar
• AbramsTAMeyerGMoloneyJPatterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC)Poster presented at: ASCO 2014 Annual Meeting [abstract 4131]
   Google Scholar
• Von HoffDDRamanathanRKBoradMJGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialJ Clin Oncol201129344548455421969517
   PubMed Web of Science ®Google Scholar
• CartwrightTHGinsburgAWilfongLSHarrellRKHovermanJRUse of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapyPoster presented at: ASCO 2014 Annual Meeting [abstract 4132]
   Google Scholar
• SantoniMBittoniAAndrikouKDoes first-line therapy affect the outcome of patients with pancreatic cancer?Poster presented at: ESMO 2014 Annual Meeting [abstract 695P]
   Google Scholar
• KrishnaKBlazerMWeiLModified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): a single institution experiencePoster presented at: ASCO 2015 Gastrointestinal Cancers Symposium [abstract 366]
   Google Scholar
• GiordanoGFebbraroAVaccaroVNab-paclitaxel (nab-P) and gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): an Italian “real life” studyPoster presented at: ESMO 2015 Annual Meeting [abstract 2334]
   Google Scholar
• HammelPBachetJBDesrameJNab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: a GERCOR randomized phase II studyPoster presented at: ASCO 2016 Annual Meeting [abstract 4120]
   Google Scholar
• ZhangDSWangDSWangZQPhase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancerCancer Chemother Pharmacol20137141065107223483298
   PubMed Web of Science ®Google Scholar
• ShenLYuXHaoJA phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (gem) for metastatic pancreatic cancer (MPC)Poster presented at: ASCO 2016 Annual Meeting [abstract 327]
   Google Scholar
• UenoHIkedaMUenoMPhase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancerCancer Chemother Pharmacol201677359560326842789
   PubMed Web of Science ®Google Scholar
• KasugaAUenoHIkedaMEfficacy, safety and pharmacokinetics of weekly nab-paclitaxel plus gemcitabine in Japanese patients with metastatic pancreatic cancer (MPC): phase I/II trialPresentation at the 2014 APA/JPS Meeting [abstract 14200]
   Google Scholar
• BachetJHammelPDesrameJNab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)Poster presented at: ESMO 2015 Annual Meeting [abstract 317]
   Google Scholar
• Lo ReGSanteufemiaDAFoltranLBidoliEBassoSMLumachiFPrognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experienceOncotarget20156108255826025779664
   PubMedGoogle Scholar
• GiordanoGDe VitaFMelisiDAnalysis of activity, efficacy and safety of first line nab-paclitaxel (nab-P) and gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)Poster presented at: ESMO 2015 Annual Meeting [abstract 297]
   Google Scholar
• ScheithauerWVon HoffDDRamanathanRDose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) vs gem alone for patients with metastatic adenocarcinoma of the pancreasPoster presented at: ESMO 2013 Annual Meeting [abstract 2.586]
   Google Scholar
• Guillen-PonceCLopezRMacarullaTA phase I/II trial to evaluate the efficacy and safety of nab-paclitaxel in combination with gemcitabine for the treatment of frail patients with advanced or metastatic pancreatic cancer: safety results of the phase I trialPoster presented at: ESMO 2014 Annual Meeting [abstract 700]
   Google Scholar
• MontesAFVillarroelPGAyerbesMVRetrospective analysis of prognostic and predictive markers in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma treated with gemcitabine/nabpaclitaxel: influence of the presence of stentPoster presented at: ASCO 2015 Annual Meeting [abstract 483]
   Google Scholar
• ParkPYSMcAfertyKVAhmadiMRadiological markers of treatment responsiveness in patients (pts) with metastatic pancreatic ductal adenocarcinomas (mPDAC) receiving systemic chemotherapyPoster presented at: ASCO 2016 Annual Meeting [abstract 403]
   Google Scholar
• BraitehFSPatelMParisiMNiQParkSYFariaCComparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology settingPoster presented at: ASCO 2016 Annual Meeting [abstract 433]
   Google Scholar
• BraitehFSPatelMParisiMNiQParkSYFariaCComparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus gemcitabine monotherapy (G) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology settingPoster presented at: ASCO 2016 Annual Meeting [abstract 429]
   Google Scholar
• WangYChenLCamaterosPGillSRenoufDJCheungWYComparative effectiveness of FOLFIRINOX or nab-paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: a population-based analysisPoster presented at: ASCO 2016 Annual Meeting [abstract 6561]
   Google Scholar
• ChioreanEGVon HoffDDTaberneroJSecond-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerBr J Cancer2016115218819427351217
   PubMed Web of Science ®Google Scholar
• GiordanoGFebbraroAMilellaMImpact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line nab-paclitaxel (nab-P) + gemcitabine (G): an Italian multicentre real life experiencePoster presented at: ASCO 2016 Annual Meeting [abstract 4124]
   Google Scholar
• SchmidtSLDurkalVJayavalsanSPOutcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG)Poster presented at: ASCO 2016 Annual Meeting [abstract 397]
   Google Scholar
• IdreesKParikhAPostlewaitLMTreatment of borderline resectable (BR) and locally advanced (LA) pancreatic cancer in the era of FOLFIRINOX and gemcitabine plus nab-paclitaxel: a multi-institutional studyPoster presented at: ASCO 2016 Annual Meeting [abstract 451]
   Google Scholar
• ClinicalTrials.govStudy of ibrutinib vs placebo, in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE) Available from: https://clinicaltrials.gov/ct2/show/NCT02436668Accessed August 1, 2015
   Google Scholar
• ClinicalTrials.govStudy of gemcitabine, ABRAXANE® plus placebo versus gemcitabine, ABRAXANE® plus 1 or 2 truncated courses of demcizumab in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma (YOSEMITE) Available from: https://clinicaltrials.gov/ct2/show/NCT02289898Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govA phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) Available from: https://clinicaltrials.gov/ct2/show/NCT02399137Accessed August 1, 2016
   Google Scholar
• HochsterHSWainbergZAGutierrezMPhase 1 study of nivolumab + nab-paclitaxel +/− gemcitabine in pancreatic cancer: safety evaluation of patients treated with nivolumab + nab-paclitaxel in arm APoster presented at: AACR: Special Conference on Pancreatic Cancer 2016 [abstract A72]
   Google Scholar
• MacKenzieSZehHMcCahillLA pilot phase II multi center study of nab-paclitaxel and gemcitabine as preoperative therapy for potentially resectable pancreatic cancer (PC)Poster presented at: ASCO 2013 Annual Meeting [abstract 4038]
   Google Scholar
• BarbourAO’RourkeNChanHInitial survival outcomes for the AGITP GAP study – a phase II study of perioperataive nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC)Poster presented at: ASCO 2016 Annual Meeting [abstract 4105]
   Google Scholar
• AlvarezRMusteanuMGarcia-GarciaEStromal disrupting effects of nab-paclitaxel in pancreatic cancerBr J Cancer2013109492693323907428
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govTrial to investigate intensified neoadjuvant chemotherapy in locally advanced pancreatic cancer (NEOLAP) Available from: https://clinicaltrials.gov/ct2/show/NCT02125136?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=55Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govPhase II study of preoperative FOLFIRINOX versus gemcitabine/nab-paclitaxel in patients with resectable pancreatic cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02243007?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=59Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govFirst line treatment of patients with metastatic pancreatic adenocarcinoma (GABRINOX) Available from: https://clinicaltrials.gov/ct2/show/NCT01964287Accessed August 1, 2016
   Google Scholar
• PhilipPALacyJDowdenSDLAPACT: an open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (gem) in patients (pts) with locally advanced pancreatic cancer (LAPC)Poster presented at: ASCO 2016 Annual Meeting [abstract TPS477]
   Google Scholar
• ClinicalTrials.govNab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the “apact” study) (apact) Available from: https://clinicaltrials.gov/ct2/show/NCT01964430?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=24Accessed August 1, 2016
   Google Scholar
• TemperoMACoussensLMFongLMangesRSinghPLiYA randomized, multicenter, double-blind, placebo-controlled study of the bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE)Poster presented at: ASCO 2016 Annual Meeting [abstract TPS483]
   Google Scholar
• ClinicalTrials.govNeoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer (NEONAX) Available from: https://clinicaltrials.gov/ct2/show/NCT02047513?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=34Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govSecond-line adjuvant therapy with nab-paclitaxel plus gemcitabine versus oxaliplatin plus folinic acid and fluorouracil for gemcitabine-refractory pancreatic cancer after curative resection Available from: https://clinicaltrials.gov/ct2/show/NCT02506842?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=42Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.gov2016 Available from: https://clinicaltrials.govAccessed August 1, 2016
   Google Scholar
• GiordanoGFebbraroAVaccaroVNab-paclitaxel (nab-P) and gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): an Italian “real life” studyPoster presented at: ESMO 2015 Annual Meeting [abstract 296]
   Google Scholar
• SueyoshiHIokaTTamuraTPhase I study of chemoradiation therapy (nab-paclitaxel/gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC)Poster presented at: ASCO 2015 Annual Meeting [abstract 475]
   Google Scholar
• DeanAPSpryNMcGrathANab-paclitaxel plus gemcitabine followed by radiotherapy with concurrent 5-fu in locally advanced unresectable pancreatic cancer: a Western Australian experiencePoster presented at: ASCO 2016 Annual Meeting [abstract 430]
   Google Scholar
• PetersonSLoaiza-BonillaABen-JosefENeoadjuvant nab-paclitaxel and gemcitabine (AG) in borderline resectable (BR) or unresectable (UR) locally advanced pancreatic adenocarcinoma (LAPC) in patients ineligible for FOLFIRINOXPoster presented at: ASCO 2016 Annual Meeting [abstract 328]
   Google Scholar
• Van LaethemJBaliMABorbathIPreoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): feasibility results and early response monitoring by diffusion-weighted (DW) MRPoster presented at: ASCO 2016 Annual Meeting [abstract 4116]
   Google Scholar
• SliesoraitisSDesaiNVTrevinoJGFinal results for gemcitabine with nab-paclitaxel in neoadjuvant treatment of resectable pancreatic adenocarcinoma: GAIN-1 studyPoster presented at: ASCO 2014 Annual Meeting [abstract e15201]
   Google Scholar
• CohenSJO’NeilBHBerlinJA phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium studyCancer Chemother Pharmacol201677469370126886016
   PubMed Web of Science ®Google Scholar
• KoAHTruongTGKantoffEA phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancerCancer Chemother Pharmacol201270687588123053263
   PubMed Web of Science ®Google Scholar
• De Jesus-AcostaAO’DwyerPJRamanathanRKA phase II study of vismodegib, a hedgehog (hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)Poster presented at: ASCO 2014 Annual Meeting [abstract 257]
   Google Scholar
• O’ReillyEMSmithLSBendellJCFinal results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, antinotch 2/3) in combination with nab-paclitaxel and gemcitabine (nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)Poster presented at: ASCO 2015 Annual Meeting [abstract 278]
   Google Scholar
• HidalgoMCoorayPCarratoAA phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/− nab-paclitaxel in patients with pancreatic cancerPoster presented at: ASCO 2016 Annual Meeting [abstract 341]
   Google Scholar
• HingoraniSBullockAHarrisWFinal analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients, utilizing VENTANA companion diagnostic assayPoster presented at: ESMO World Congress on Gastrointestinal Cancers 2016 [abstract PD-006]
   Google Scholar
• HingoraniSRHarrisWPSeeryTEInterim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancerPoster presented at: ASCO 2016 Annual Meeting [abstract 439]
   Google Scholar
• BullockAJHingoraniSRWuXWFinal analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer (pts), utilizing VENTANA companion diagnostic assayPoster presented at: ASCO 2016 Annual Meeting [abstract 4104]
   Google Scholar
• O’ReillyEMMahalingamDRoachJMSafety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: updated phase 1 resultsPoster presented at: ASCO 2016 Annual Meeting [abstract 4117]
   Google Scholar
• BhattacharyyaGSBabuKGBondardeSAEffect of coadministered beta blocker and cox-2 inhibitors to patients with pancreatic cancer prior to receiving albumin-bound paclitaxelPoster presented at: ASCO 2015 Annual Meeting [abstract 302]
   Google Scholar
• MahipalASpringettGMBurkeNPhase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancerPoster presented at: ASCO 2015 Annual Meeting [abstract 467]
   Google Scholar
• ReniMBelliCBalzanoGPhase IB trial of nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with stage III pancreatic adenocarcinomaPoster presented at: ESMO World Congress on Gastrointestinal Cancer 2014 [abstract 711P]
   Google Scholar
• SigalDMarcusSGRosenPJAssociation of 2-O, 3-O desulfated heparin (ODSH) plus combination gemcitabine (G)/nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancer plus combination gemcitabine (G)/nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancerPoster presented at: ASCO 2013 Annual Meeting [abstract 284]
   Google Scholar
• KoAHMurphyPBPeytonJDA randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (pl) in patients (pts) with metastatic pancreatic cancer (mPC): the RAINIER trialPoster presented at: ASCO 2016 Annual Meeting [abstract 4119]
   Google Scholar
• El-RayesBFShahdaSStarodubAO’NeilBHHannaWTOhCA phase Ib extension study of cancer stemness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancerPoster presented at: ASCO 2016 Annual Meeting [abstract 4128]
   Google Scholar
• BaharyNGarrido-LagunaIWang-GillamAResults of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancerPoster presented at: ASCO 2016 Annual Meeting [abstract 452]
   Google Scholar
• BoradMJKwakELWang-GillamAIbrahimAAldridgeJOlszanskiAJEvofosfamide combined with gemcitabine/nab-paclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): results of a phase I trialPoster presented at: ASCO 2016 Annual Meeting [abstract 4114]
   Google Scholar
• ClinicalTrials.govQuality of life study in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel (QOLINPAC) Available from: https://clinicaltrials.gov/ct2/show/NCT02106884?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=54Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govFirst-line treatment of metastatic pancreatic cancer with nab-paclitaxel and gemcitabine (ALPACA) Available from: https://clinicaltrials.gov/ct2/show/NCT02564146?term=NCT02564146&rank=1Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govGemcitabine and nab-paclitaxel combined with momelotinib in participants with previously untreated metastatic pancreatic ductal adenocarcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT02101021Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govA study of PEGylated recombinant human hyaluronidase in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in participants with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT02715804Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govStudy of nanoliposomal irinotecan (nal-IRI)-containing regimens in patients with previously untreated, metastatic pancreatic adenocarcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT02551991Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govSequential treatment of nab-paclitaxel + gemcitabine / FOLFIRI.3 vs nab-paclitaxel + gemcitabine in 1st line treatment of metastatic pancreatic cancer (FIRGEMAX) Available from: https://clinicaltrials.gov/ct2/show/NCT02827201Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govPhase I/II study of nab-paclitaxel and gemcitabine followed by AG-mFOLFOX in patients with metastatic pancreatic adenocarcinoma (SEQUENCE) Available from: https://www.clinicaltrials.gov/ct2/show/NCT02504333Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govA phase I-II study of PAXG in stage III-IV pancreatic adenocarcinoma (PACT-19) Available from: https://clinicaltrials.gov/ct2/show/NCT01730222?term=nab-paclitaxel+AND+pancreatic+AND+adenocarcinoma&rank=12Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govPhase I/II study to evaluate nab-paclitaxel in substitution of CPT11 or oxaliplatin in FOLFIRINOX schedule as first line treatment in metastatic pancreatic cancer (NabucCO) Available from: https://clinicaltrials.gov/ct2/show/NCT02109341Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govPaclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochoride with or without WEE1 inhibitor MK-1775 in treating patients with previously untreated pancreatic cancer that is metastatic or cannot be removed by surgery Available from: https://clinicaltrials.gov/ct2/show/NCT02194829Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govPhase 2 nab™-paclitaxel (Aabraxane^®) plus gemcitabine in subjects with locally advanced pancreatic lancer (LAPC) (LAPACT) Available from: http://www.clinicaltrials.gov/ct2/show/NCT02301143Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govS1505: combination chemotherapy or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02562716Accessed September 15, 2016
   Google Scholar
• ClinicalTrials.govPancreas cancer: molecular profiling as a guide to therapy before and after surgery (“personalized medicine”) Avalable from: https://clinicaltrials.gov/ct2/show/NCT02562716Accessed August 1, 2016
   Google Scholar
• ClinicalTrials.govSystemic therapy and chemoradiation in advanced localised pancreatic cancer-2 (SCALOP-2) Available from: https://clinicaltrials.gov/ct2/show/NCT02024009Accessed August 1, 2016
   Google Scholar